This "T cell lymphoma - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in T cell lymphoma pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
T cell lymphoma Emerging Drugs Chapters
This segment of the T cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T cell lymphoma Emerging Drugs
SGX301 is a photodynamic therapy using synthetically manufactured hypericin in an ointment combined with visible fluorescent light. Hypericin is one of the most photoactive compounds known - it is easily activated with relatively low energy light. This makes it ideal for photodynamic therapy because it can be activated with fluorescent light, instead of UV A or UV B light, which are associated with increased cancer risks.
Synthetic hypericin, the active ingredient in SGX301, tends to accumulate in T-cells. Once the hypericin is in the T-cells, it can be activated by safe, visible fluorescent light. When synthetic hypericin is activated it creates oxygen radicals which subsequently cause cellular toxicity, killing the targeted T-cells. It is currently in Phase III stage of development for Cutaneous T-cell lymphoma and is being developed by Soligenix.
SP-02: Solasia Pharma
SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. In a Phase II study in the U.S. Intravenous darinaparsin demonstrated evidence of clinical activity in malignant lymphoma, and in particular peripheral T-cell lymphoma (PTCL). Darinaparsin was granted Orphan Drug Designation in the U.S. and Europe as a treatment of PTCL and Solasia intends to seek similar status in Japan.
It is currently in Phase III stage of development for the treatment of peripheral T-cell lymphoma (PTCL) and is being developed by Solasia Pharma.
Major Players working on T cell lymphoma
There are approx. 100+ key companies which are developing the T cell lymphoma. The companies which have their T cell lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Soligenix.
T cell lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T cell lymphoma therapeutic drugs key players involved in developing key drugs.
Current Scenario and Emerging Therapies:
How many companies are developing T cell lymphoma drugs?
How many T cell lymphoma drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for T cell lymphoma?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the T cell lymphoma therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for T cell lymphoma and their status?
What are the key designations that have been granted to the emerging drugs?
CSPC ZhongQi Pharmaceutical Technology
Shanghai YingLi Pharmaceutical
Chia Tai Tianqing Pharmaceutical Group
Nanjing Sanhome Pharmaceutical
Rhizen Pharmaceuticals SA
Millennium Pharmaceuticals, Inc.
HUYA Bioscience International
Shandong New Time Pharmaceutical Co., LTD
Janssen Research & Development
Hebei Senlang Biotechnology Inc.
Merck Sharp & Dohme
Eli Lilly and Company
Yake Biotechnology Ltd.
Akeso Pharmaceuticals, Inc.
Trillium Therapeutics Inc.
TG Therapeutics, Inc.
PersonGen BioTherapeutics (Suzhou) Co
Bio-Path Holdings, Inc.
Corvus Pharmaceuticals, Inc.
iCell Gene Therapeutics
Boryung Pharmaceutical Co., Ltd
ADC Therapeutics S.A.
Legend Biotech USA Inc
Nanatinostat + Valganciclovir
L-Bcl-2 antisense oligonucleotide
ICAR30 T cells
CD4 CAR T cells
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/o2ri8e
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005573/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900